Pulmonary effects of prolonged oligohydramnios following mid-trimester rupture of the membranes--antenatal and postnatal management

Neonatology. 2012;101(2):83-90. doi: 10.1159/000329445. Epub 2011 Sep 17.

Abstract

Mid-trimester, preterm prelabour rupture of the membranes (PPROM) with prolonged oligohydramnios remains a challenge for both obstetricians and neonatologists. Although survival rates have improved, morbidity remains common particularly due to pulmonary insufficiency and pulmonary hypertension. The aetiology of abnormal lung development is unknown but may depend critically on pulmonary vascular development. Antenatal evaluation of at-risk foetuses by three-dimensional ultrasound and MRI is possible but the techniques need to be further assessed. Antenatal corticosteroids given in cases of PPROM reduce the incidence of neonatal death, respiratory distress syndrome, intraventricular haemorrhage and necrotising enterocolitis without increasing maternal or neonatal infection. The true risk-benefit ratio of antibiotics, tocolysis and strategies to normalise amniotic fluid volume remains less clear. There is no consensus regarding the optimal ventilation strategy to support infants with pulmonary insufficiency following PPROM, and further work is required to determine whether and which pulmonary vasodilators improve long-term outcome in these infants.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Cerebral Hemorrhage / drug therapy
  • Cerebral Hemorrhage / prevention & control
  • Enterocolitis, Necrotizing / drug therapy
  • Enterocolitis, Necrotizing / prevention & control
  • Female
  • Fetal Membranes, Premature Rupture / diagnosis
  • Fetal Membranes, Premature Rupture / therapy*
  • Humans
  • Infant, Newborn
  • Lung / growth & development
  • Lung Diseases / drug therapy
  • Oligohydramnios / diagnosis
  • Oligohydramnios / therapy*
  • Pregnancy
  • Respiration, Artificial
  • Respiratory Distress Syndrome, Newborn / drug therapy
  • Respiratory Distress Syndrome, Newborn / prevention & control

Substances

  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents